Free Trial
NASDAQ:ADGM

Adagio Medical Q2 2026 Earnings Report

Adagio Medical logo
$0.14 0.00 (-2.20%)
Closing price 04:00 PM Eastern
Extended Trading
$0.14 +0.00 (+2.17%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adagio Medical EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.27
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Adagio Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adagio Medical Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Adagio Medical's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Adagio Medical Earnings Headlines

Adagio Medical Converts Notes to Equity Amid Review
Adagio Medical (NASDAQ:ADGM) & Femasys (NASDAQ:FEMY) Financial Review
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
See More Adagio Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adagio Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagio Medical and other key companies, straight to your email.

About Adagio Medical

Adagio Medical (NASDAQ:ADGM), Inc. is a medical-device company focused on developing catheter-based technologies for the treatment of cardiac arrhythmias, including atrial fibrillation. The company’s work is centered on cardiac ablation, a procedure that uses energy to create targeted lesions in heart tissue responsible for abnormal electrical signals.

Its lead technology is the iCLAS system, an integrated cardiac liquid ablation platform designed to support cardiac ablation procedures using ultra-low-temperature cryoablation and pulsed-field ablation capabilities. The system is intended to help physicians treat arrhythmias through catheter-based procedures, with potential applications that include persistent atrial fibrillation and other complex rhythm disorders. Product availability and regulatory authorization may vary by geography and indication.

Adagio Medical was founded in 2011 and is based in Laguna Hills, California. The company has focused primarily on research, clinical development and regulatory advancement of its ablation platform, serving the global electrophysiology and cardiovascular-care markets. Its leadership has included founder and Chief Executive Officer Olav Bergheim.

View Adagio Medical Profile